ProKidney Analyst Ratings
ProKidney Analyst Ratings
B of A Securities Maintains Neutral on ProKidney, Raises Price Target to $4
Buy Rating Affirmed for ProKidney on Rilparencel's Promising Efficacy in CKD Treatment
Maintaining Hold on ProKidney: Balancing Market Potential Against Clinical Uncertainties
Buy Rating Affirmed for ProKidney Amidst Strategic Clinical Advancements and Solid Financial Outlook
ProKidney Analyst Ratings
Analysts Conflicted on These Healthcare Names: ProKidney (PROK), Gritstone Oncology (GRTS) and MicroPort Scientific (OtherMCRPF)
BTIG Reaffirms Their Buy Rating on ProKidney (PROK)
B of A Securities Downgrades ProKidney to Neutral, Lowers Price Target to $2
ProKidney Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), Palatin Technologies (PTN) and ProKidney (PROK)
ProKidney's Future Promising: REACT Trial Success and Strategic Enrollment Shift Boosts Buy Rating
BTIG Initiates Coverage On ProKidney With Buy Rating, Announces Price Target of $16
ProKidney Analyst Ratings
Analysts Offer Insights on Healthcare Companies: ProKidney (PROK) and Enliven Therapeutics (ELVN)
Jefferies Initiates Coverage On ProKidney With Buy Rating, Announces Price Target of $15
Morgan Stanley Initiates Coverage On ProKidney With Equal-Weight Rating, Announces Price Target of $13
UBS Initiates Coverage on ProKidney With Buy Rating, $18 Price Target
BofA Securities Starts ProKidney at Buy With $14 Price Target